Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria

Name: Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria
Creator: Katrine Baumann
Published: 2023-06-22T06:24:38.423Z
Keywords: Dermatology, Allergology

Baumann, Katrine; Jørgensen, Astrid-Helene Ravn; Sørensen, Jennifer Astrup; Zhang, Ditte; Ghazanfar, Misbah Noshela; Skov, Per Stahl; Woetmann, Anders; Vestergaard, Christian; Maurer, Marcus; Thomsen, Simon Francis

doi:10.17632/43y6kcf6pg.1

Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria

Published: 22 June 2023| Version 1 | DOI: 10.17632/43y6kcf6pg.1

Contributors:

Katrine Baumann, Astrid-Helene Ravn Jørgensen, Jennifer Astrup Sørensen, Ditte Zhang, Misbah Noshela Ghazanfar, Per Stahl Skov, Anders Woetmann, Christian Vestergaard, Marcus Maurer, Simon Francis Thomsen

Description

Supplementary material for article published in Clinical Experimental Allergy (Baumann et al): Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria

Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria

Description

Files

Categories

Licence